14.3 Temporary & Permanent Contraceptive Methods in India

14.3 Temporary & Permanent Contraceptive Methods in India

Family Planning is a key component of national health policy in India. India was the first country in the world to initiate a National Family Planning Programme in 1952. Under the modern Reproductive, Maternal, Newborn, Child and Adolescent Health (RMNCH+A) strategy and Mission Parivar Vikas, the government has expanded the 'Basket of Choice' to ensure universal access to high-quality spacing and permanent contraceptive modalities.

---

Quantifying Efficacy: The Pearl Index

Contraceptive efficacy is evaluated objectively using the Pearl Index, defined as the number of unintended pregnancies per 100 woman-years of exposure (equivalent to 1,200 months of use):

$\text{Pearl Index} = \frac{\text{Total Unintended Pregnancies} \times 1200}{\text{Total Months of Exposure (or Woman-Months)}}$

A lower Pearl Index indicates higher contraceptive efficacy. Clinical guidelines distinguish between Perfect Use (failure rate under ideal, error-free trial conditions) and Typical Use (failure rate reflecting real-world inconsistent or incorrect use).

---

Temporary (Spacing) Contraceptive Methods

1. Combined Oral Contraceptive Pills (COCPs - Mala-N & Mala-D)

• Composition: 21 active hormonal tablets containing Levonorgestrel 0.15 mg (150 mcg) + Ethinylestradiol 0.03 mg (30 mcg), followed by 7 brown iron tablets (Ferrous Fumarate 60 mg) to maintain daily pill-taking habits and treat anemia.
  • Mala-N: Distributed free of charge in government health facilities.
  • Mala-D: Socially marketed at a subsidized price.
• Mechanism of Action: Ethinylestradiol suppresses pituitary FSH secretion (inhibiting follicular development), while progestin suppresses the LH surge (preventing ovulation), thickens cervical mucus (impeding sperm transport), and alters the endometrium.
• WHO Medical Eligibility Criteria (Category 4 - Absolute Contraindications):
  • Age >35 years and heavy smoker (≥15 cigarettes/day).
  • History of or current Venous Thromboembolism (DVT / Pulmonary Embolism).
  • Ischemic heart disease, stroke, or complicated valvular heart disease.
  • Severe hypertension (SBP ≥160 mmHg or DBP ≥100 mmHg).
  • Breast cancer (current or within past 5 years).
  • Migraine with focal neurological aura at any age.
  • Acute hepatitis, severe cirrhosis, or liver tumors.

2. Centchroman / Ormeloxifene (Chhaya / Saheli)

• Unique Indian Innovation: Developed by the Central Drug Research Institute (CDRI), Lucknow. It is a non-steroidal, non-hormonal Selective Estrogen Receptor Modulator (SERM).
• Mechanism of Action: Acts as an estrogen antagonist in the endometrium (rendering it unreceptive to blastocyst implantation) and accelerates tubal transport of ova. Crucially, it does not suppress ovulation or disrupt the hypothalamic-pituitary-ovarian axis.
• Dosing Schedule: 30 mg tablet taken twice weekly for the first 12 weeks (e.g., Sunday and Wednesday), followed by 30 mg once weekly thereafter (on the first day taken).
• Side Effect Profile: Highly safe with no risk of thromboembolism, weight gain, or hormonal neoplasia. The primary side effect is a benign delay in menses in ~8% of cycles.

3. Injectable Progestin Contraceptives (Antara Program)

• DMPA (Depot Medroxyprogesterone Acetate): 150 mg IM deep gluteal/deltoid injection every 3 months (12 weeks).
• NET-EN (Norethisterone Enanthate): 200 mg IM injection every 2 months (8 weeks).
• Mechanism: Sustained progestin levels inhibit LH surge (preventing ovulation) and thicken cervical mucus.
• Clinical Considerations: High incidence of menstrual irregularities (irregular spotting initially, progressing to complete amenorrhea in >50% of users by 1 year). Prolonged use (>2 years) causes reversible loss of bone mineral density (BMD). Return of fertility may be delayed by 6 to 10 months post-discontinuation.

4. Intrauterine Contraceptive Devices (IUCDs)

• Copper IUCDs (Cu-T 380A & Cu-T 375):
  • Cu-T 380A: Active duration of 10 years. Features 380 mm² of surface copper wire wrapped around the stem and solid copper sleeves on the horizontal arms.
  • Cu-T 375: Active duration of 5 years.
  • Mechanism: Copper ions induce a localized, sterile, foreign-body inflammatory response within the endometrium, producing cytotoxic effects on spermatozoa and preventing fertilization.
  • Timing of Insertion: Interval (within 7 days of menses onset), Postpartum (PPIUCD within 10 minutes of placental delivery or up to 48 hours postpartum), or Post-abortal.
  • Complications: Menorrhagia and dysmenorrhea (most common reason for removal), uterine perforation (~1 in 1,000, highest in lactating women), and expulsion (~5-10%).
• Hormone-Releasing IUCD (LNG-IUS / Mirena / Chhaya-IUS):
  • Releases 20 mcg levonorgestrel daily into the uterine cavity; active for 5 to 8 years.
  • Induces profound localized endometrial atrophy; primary medical treatment for heavy menstrual bleeding.

5. Emergency Contraceptive Pills (ECPs)

• Levonorgestrel (LNG 1.5 mg single dose / E-Pill): Must be taken within 72 hours of unprotected coitus. Prevents or delays ovulation. Ineffective once blastocyst implantation has occurred.
• Ulipristal Acetate (30 mg single dose): Progesterone receptor modulator effective up to 120 hours (5 days).
• Copper-T 380A: Inserted up to 5 days post-unprotected intercourse; most effective emergency contraceptive modality (>99% reduction in pregnancy risk).

---

Permanent Contraceptive Methods (Sterilization)

1. Female Sterilization (Tubal Ligation)

• Techniques:
  • Pomeroy Technique: Most widely performed abdominal method. A loop of the mid-ampullary portion of the fallopian tube is elevated, ligated at its base with absorbable suture (chromic catgut), and the top of the loop is resected.
  • Laparoscopic Occlusion: Application of Filshie clips or Falope rings (silastic bands) to the ampullary-isthmic junction.
• Timing:
  • Puerperal / Postpartum Sterilization: Performed within 24–48 hours post-delivery via a small subumbilical minilaparotomy incision.
  • Interval Sterilization: Performed during the follicular phase of the menstrual cycle.
• Failure Rate: ~0.5% (1 in 200). If pregnancy occurs post-ligation, ectopic pregnancy must be ruled out immediately.

2. Male Sterilization (No-Scalpel Vasectomy - NSV)

• Technique: Performed under local anesthesia. The vas deferens is isolated using a specialized ring-pinning forceps through a single tiny puncture in the anterior scrotal skin (no incision/scalpel used). A 1 cm segment of the vas is excised, and the cut ends are ligated and cauterized.
• Post-Procedure Protocol & Verification: Vasectomy does NOT result in immediate sterility due to viable spermatozoa stored in the distal vas deferens and seminal vesicles.
  • Patient must use alternative barrier contraception for 3 months or 20 ejaculations post-procedure.
  • Sterility is confirmed only when a Post-Vasectomy Semen Analysis (PVSA) performed at 3 months demonstrates complete azoospermia (or <100,000 non-motile sperm/mL).

---

Contraceptive Efficacy & Failure Rate Comparison